Elliot Philips

Physician-scientist, MD-PhD from NYU SoM, PhD studying structure/function of immune checkpoint receptors, NYU/Bellevue IM residency & Rheumatology Fellowship

[Elliot Philips @Elliot_Philips]

Ecstatic that my thesis work got published today! — Transmembrane domain–driven PD-1 dimers mediate T cell inhibition | Science Immunology https://t.co/GhUuBwkkU7
@SciImmunology @MichaelLDustin @jwang133 #ImmunoTherapy #ImmuneCheckpoint #Immunology

[Elliot Philips @Elliot_Philips]

@hui_enfu @SciImmunology @MasubuchiTakeya @hui_enfu very interesting, thanks for sharing! Coupled with our 2020 JBC paper (https://t.co/78hmtubDUY) which described the evolutionary divergence of PD-L2 from PD-L1, we now have a comprehensive understanding of PD-1-axis evolution

[NYU Department of Medicine @NYULH_DeptofMed]

We're pleased to announce the launch of our new Rheumatology Fellowship Research Track, in the Division of Rheumatology, led by Dr. Jill Buyon. The new Research Track is designed to advance career pathways in research within #Rheumatology & the broader field of Medicine. Dr. Buyon, Program Director Dr. Michael Pillinger (@MHPillingerMD), & Dr. Jose Scher will play key roles as faculty educators & mentors. Welcome & congratulations to our inaugural Research Track fellows: Dr. Phil Carlucci, Dr. Marcus Hines, & Dr. Elliot Philips

#FutureofMedicine #FutureofResearch&Innovation

[NYU Department of Medicine @NYULH_DeptofMed]

Impressive Med #GrandRounds at @nyugrossman - highlighting our Resident Research Showcase! Congratulations to Dr. Ying Liu, Dr. Elliot Philips, & Dr. Aaron Tabibzadeh on their outstanding work and presentations. #ResidentResearchShowcase #Research #FutureofMedicine #MedTwitter @Yi@YingLiu898 @Elliot_Philips @glennfishman @PopovVioleta @ElaineShumMD

[Elliot Philips @Elliot_Philips]

Thank you @NIHDirector for highlighting our paper revealing the mechanism of PD-1 dimerization on the NIH Director’s Blog! https://t.co/f5OSVwtEej
#Immunotherapy @MichaelLDustin @jwang133 @nyulangone @SciImmunology https://t.co/Pq4ZE9dNKR

[Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC]

A new study from @NYUGSOM_Path suggests that PD-1 receptor dimerization may reveal new strategies to improve the efficacy of anticancer immunotherapies.

Learn about the findings from our investigators Drs. @jwang133, @Elliot_Philips, and Xiangpeng Kong: https://t.co/MFPgAw8syS

[Science Magazine @ScienceMagazine]

The immunotherapeutic target #PD1 receptor forms dimers—rather than monomers—to limit anti-tumor T cell activity during #cancer, finds new @SciImmunology work in vitro and in mice. https://t.co/cGYHvu0iVo

[Benita Wolf @benita_wolf1]

PD-1 forms homo-dimers in cis on T cells via transmembrane domain. Congrats to all authors around @MichaelLDustin, Xiang-Peng Kong, Elliot A. Philips, Jun Wang

Transmembrane domain–driven PD-1 dimers mediate T cell inhibition | Science Immunology https://t.co/urLLuoRel4

[Jun Wang @jwang133]

Our LAG-3 dimer paper is finally out at @PNASNews! Great collaboration with Dr. Jennifer Cochran @Stanford and Dr. Xiangpeng Kong @nyulangone! Warm congratulations to talented students #JasperDu and #JohnSilberstein!! Many thanks to fundings from @NIH @MelanomaReAlli

[Jun Wang @jwang133]

My great pleasure to assist Dr. Kong and his talented student @Elliot_Philips, and @MichaelLDustin to finish this interesting study @SciImmunology on PD1 biology! Great collaboration between @nyulangone and @UniofOxford!

[Jack Silberstein @Jack_Silb]

I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3

Link to paper: https://t.co/tTqz8a9aIw

Link to press release: https://t.co/BotEe86ztR

[Science Immunology @SciImmunology]

As well as addressing a longstanding debate about #PD1 dimerization, a new study in vitro and in mice further establishes that dimerization assists PD-1 in inhibiting T cell #autoimmunity. @MichaelLDustin @jwang133 @nyugrossman

📄: https://t.co/riNddc2aWd

[Science Magazine @ScienceMagazine]

The immunotherapeutic target #PD1 receptor forms dimers—rather than monomers—to limit anti-tumor T cell activity during #cancer, finds new @SciImmunology work in vitro and in mice. https://t.co/P47Yc0K42K

[Kennedy Institute of Rheumatology @KirOxford]

PD-1 is an important target for cancer therapeutics, with anti-PD-1 antibodies used successfully in the clinic.

A new study in @SciImmunology shows that PD-1 can form homodimers, giving fresh clues to its function & how we could improve patient outcomes.

https://t.co/rC9qaEKBXj

[Science Immunology @SciImmunology]

The immunotherapeutic target #PD1 receptor forms dimers—rather than monomers—to limit anti-tumor T cell activity during #cancer, finds new work in vitro and in mice. @MichaelLDustin @jwang133 @nyugrossman

📄: https://t.co/NLQ8V19OMI

[Eric Topol @EricTopol]

🆕 @SciImmunology
Contrary to science dogma, the programmed cell death (PD-1) receptor on immune cells exists as a dimer (not just as a monomer). Its stimulation (checkpoint agonist) may be well suited to treat/prevent autoimmune diseases
https://t.co/5rtbi4tzIE @Elliot_Philips

[Waggoner Lab @LabWaggoner]

PD-1 and its ligands dimerize in cis via transmembrane domain interactions to enhance T cell inhibition @jwang133 @SciImmunology @MichaelLDustin
https://t.co/b3HgPh305s

[Waggoner Lab @LabWaggoner]

Antibody agonists trigger receptor signaling by locally excluding receptor-type protein tyrosine phosphatases from sites of antibody-receptor engagement @ImmunityCP @lippert_lab
https://t.co/NaXBtwtN4Z

[Elliot Philips @Elliot_Philips]

Editor’s Pick Highlight of this article written by reviewers @MichaelLDustin and Ana Zenclussen: A checkpoint cliffhanger at the dawn of placental mammals - Journal of Biological Chemistry https://t.co/Y7EJcYsrU2

[Elliot Philips @Elliot_Philips]

The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals - Journal of Biological Chemistry https://t.co/LxkqHQyqBn
#ImmuneCheckpoint #StructuralBiology #Evolution #Immunology @jbiolchem